CDMO– tag –
-
Off-the-Shelf Advantage: How Scalable Manufacturing Drives Clinical Success for Combination Cell Therapies
Industry Publication USA Overview A recent industry analysis underscores the critical role of manufacturability and scalability from the earliest stages of development for the clinical success of cell therapies, particularly complex comb... -
Gene Therapy Manufacturing: Viral Vector CDMOs Confront Oversupply Amidst Rapid Expansion
IntuitionLabs USA Overview A recent industry report offers a comparative analysis of the AAV and lentiviral vector CDMO market, revealing trends of consolidation and emerging capacity oversupply. It highlights key players like FUJIFILM D... -
AGC Biologics Commits Half of New Yokohama Biomanufacturing Plant to Major Long-Term Deal
Megaproject Japan Overview AGC Biologics has secured a significant multi-million dollar, long-term commercial manufacturing contract with an undisclosed pharmaceutical firm for its new Yokohama facility, set to open in 2027. This landmar... -
Leading CDMOs Lonza, Samsung Biologics, Charles River Laboratories Spearhead Viral Vector Production, Legend Biotech Drives CAR-T Commercialization
GENE ONLINE|News & Opinion. Blog USA Overview Lonza, Samsung Biologics, and Charles River Laboratories are leading the complex viral vector manufacturing essential for scaling cell and gene therapies (CGTs), while Legend Biotech is drivi... -
AsymBio Secures $184 Million in Funding to Expand Biologics CDMO Operations, Boosting ADC and Bispecific Antibody Manufacturing Capacity
Pharma Manufacturing China Overview Shanghai-based biologics CDMO AsymBio has successfully raised approximately $184 million (RMB 1.24 billion) in new funding to significantly expand its biologics development and manufacturing operations... -
Resilience and Eli Lilly Invest $750 Million to Boost U.S. Medicine Supply, Expanding Biologics, Cell Therapy, and Aseptic Manufacturing
Resilience USA Overview Resilience has announced a $750 million investment in new pharmaceutical manufacturing in Ohio, expanding its strategic partnership with Eli Lilly to bolster the U.S. medicine supply. Resilience operates as a comp... -
Swiss Bachem Invests Over $431M in 2026 to Meet Surging Global Peptide and Oligonucleotide Demand with New Facility
Pharma Manufacturing Switzerland Overview Bachem, a Swiss CDMO specializing in peptides and oligonucleotides, is undertaking a major manufacturing capacity expansion across its global network, investing between $431 million and $493 mill... -
Asia-Pacific Revolutionizes Pharma Manufacturing: Surging Capabilities in HPAPIs, Biologics, and Advanced Therapies
BioProcess International Asia-Pacific Overview The Asia-Pacific (APAC) region is rapidly expanding its specialized pharmaceutical manufacturing capabilities beyond traditional APIs, focusing on high-value modalities like HPAPIs, ADCs, mR... -
AAV Vector Manufacturing Achieves Kilo-Scale Production with 2,000L+ Suspension Bioreactors, Solving Gene Therapy Bottleneck
Drug Discovery News USA Overview AAV upstream production has achieved significant scalability, with suspension bioreactors reaching over 2,000 liters using adapted HEK293 cells, providing volumetric capacity for clinical and commercial g... -
Viral Vector CDMO Capacity Exceeds Clinical Demand: Catalent and Lonza Lead AAV Manufacturing Expansion
IntuitionLabs USA Overview An August 2026 analyst report reveals that viral vector manufacturing capacity, especially for AAV, has outpaced current clinical demand, offering gene therapy sponsors more options and competitive lead times. ...
